Dr. Madi Madiyalakan reports

QUEST PHARMATECH ANNOUNCES RESULTS FROM AGM

Quest Pharmatech Inc. has released the results of its Aug. 25, 2025, annual general meeting of shareholders.

The company announces the following four directors have been re-elected to the company's board of directors:

• J. Mark Lievonen, CM, FCPA, FCA, LLD;
• Jeffrey Shon, JD;
• Madi R. Madiyalakan, PhD;
• Bradley J. Glass, JD.

At the meeting, shareholders reappointed the company's auditor, Kingston Ross Pasnak LLP.

"I would like to thank all of our board members for their service to the company," said Dr. Madi R. Madiyalakan, chief executive officer of Quest. "I am confident that Quest's board of directors will be able to help the company execute its business strategy to add value to our shareholders."

Approximately 50,288,000 shares were voted for the company's shareholder meeting representing approximately 29.7 per cent of the company's shares eligible to vote.

On a corporate matter, Quest announces the granting of 1.9 million stock options to directors and officers, all at a volume weighted average exercise price of five cents per common share, expiring 10 years from the date of grant, subject to TSX Venture Exchange approval.

About Quest Pharmatech Inc.

Quest Pharmatech is a publicly traded, Canadian based biopharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies. Quest is developing the proprietary MAb-AR9.6 targeting MUC16 as theranostic agents for cancer. MAb-AR9.6 was licensed from the University of Nebraska Medical Centre and currently is in late preclinical stage development. The company also has a 42.5-per-cent ownership interest in OncoQuest Inc. which sold its immunotherapy technology assets to Korea-based Dual Industrial Co. Ltd. in April, 2020. Quest also has a 23-per-cent ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory.

We seek Safe Harbor.